Literature DB >> 26823152

Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.

Lisandro D Colantonio1, Shia T Kent1, Meredith L Kilgore2, Elizabeth Delzell1, Jeffrey R Curtis1,3, George Howard4, Monika M Safford3, Paul Muntner1,3.   

Abstract

BACKGROUND: Medicare claims have been used to study lipid-lowering medication (LLM) use among US adults.
METHODS: We analyzed the agreement between Medicare claims for LLM and LLM use indicated by self-report during a telephone interview and, separately, by a medication inventory performed during an in-home study visit upon enrollment into the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. We included REGARDS participants ≥65 years enrolled in 2006-2007 with Medicare pharmacy benefits (Part D) from 120 days before their telephone interview through their medication inventory (n = 899).
RESULTS: Overall, 39.2% and 39.5% of participants had a Medicare claim for an LLM within 120 days prior to their interview and medication inventory, respectively. Also, 42.7% of participants self-reported using LLMs, and 41.8% had an LLM in their medication inventory. The Kappa statistic (95% confidence interval [CI]) for agreement of Medicare claims with self-report and medication inventory was 0.68 (0.63-0.73) and 0.72 (0.68-0.77), respectively. No Medicare claims for LLMs were present for 22.1% (95%CI: 18.1-26.6%) of participants who self-reported taking LLMs and 18.9% (15.1-23.3%) with LLMs in their medication inventory. Agreement between Medicare claims and self-report was lower among Black male individuals (Kappa = 0.34 [95%CI: 0.14-0.54]) compared with Black female individuals (0.70 [0.61-0.79]), White male individuals (0.65 [0.56-0.75]), and White female individuals (0.79 [0.72-0.86]). Agreement between Medicare claims and the medication inventory was also low among Black male individuals (Kappa = 0.48 [95%CI: 0.29-0.66]).
CONCLUSIONS: Although substantial agreement exists, many Medicare beneficiaries who self-report LLM use or have LLMs in a medication inventory have no claims for these medications.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Medicare Part D; drug; drug prescriptions; hydroxymethylglutaryl-CoA reductase inhibitors; insurance claim review; pharmacoepidemiology; utilization

Mesh:

Substances:

Year:  2016        PMID: 26823152      PMCID: PMC5039944          DOI: 10.1002/pds.3970

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  33 in total

1.  The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.

Authors:  Bobby L Clark; John Hou; Chia-Hung Chou; Elbert S Huang; Rena Conti
Journal:  Health Aff (Millwood)       Date:  2014-11       Impact factor: 6.301

2.  Comparability of self-reported medication use and pharmacy claims data.

Authors:  Sara Allin; Ahmed M Bayoumi; Michael R Law; Audrey Laporte
Journal:  Health Rep       Date:  2013-01       Impact factor: 4.796

3.  Medicare Part D Enrollees' Use of Out-of-Plan Discounted Generic Drugs, Revisited.

Authors:  Jonathan Harding
Journal:  J Am Geriatr Soc       Date:  2013-02       Impact factor: 5.562

4.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

5.  Assessing Medicare Part D claim completeness using medication self-reports: the role of veteran status and Generic Drug Discount Programs.

Authors:  Lei Zhou; Sally C Stearns; Emily M Thudium; Khalid A Alburikan; Jo E Rodgers
Journal:  Med Care       Date:  2015-05       Impact factor: 2.983

6.  Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?

Authors:  Alexandra Tungol; Catherine I Starner; Brent W Gunderson; Jeremy A Schafer; Yang Qiu; Patrick P Gleason
Journal:  J Manag Care Pharm       Date:  2012 Nov-Dec

7.  Completeness of prescription information in US commercial claims databases.

Authors:  Julie C Lauffenburger; Akhila Balasubramanian; Joel F Farley; Cathy W Critchlow; Cynthia D O'Malley; Mary T Roth; Virginia Pate; M Alan Brookhart
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-05-21       Impact factor: 2.890

8.  Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010.

Authors:  Paul Muntner; Emily B Levitan; Todd M Brown; Pradeep Sharma; Hong Zhao; Vera Bittner; Stephen Glasser; Meredith Kilgore; Huifeng Yun; J Michael Woolley; Michael E Farkouh; Robert S Rosenson
Journal:  Am J Cardiol       Date:  2013-05-29       Impact factor: 2.778

9.  A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies.

Authors:  T P van Staa; L Abenhaim; H Leufkens
Journal:  J Clin Epidemiol       Date:  1994-02       Impact factor: 6.437

10.  Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio.

Authors:  Aluísio J D Barros; Vânia N Hirakata
Journal:  BMC Med Res Methodol       Date:  2003-10-20       Impact factor: 4.615

View more
  13 in total

1.  A systematic review of methods for determining cross-sectional active medications using pharmacy databases.

Authors:  Timothy S Anderson; Edison Xu; Evans Whitaker; Michael A Steinman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-13       Impact factor: 2.890

2.  Cardiovascular Health and Incident Hypertension in Blacks: JHS (The Jackson Heart Study).

Authors:  John N Booth; Marwah Abdalla; Rikki M Tanner; Keith M Diaz; Samantha G Bromfield; Gabriel S Tajeu; Adolfo Correa; Mario Sims; Gbenga Ogedegbe; Adam P Bress; Tanya M Spruill; Daichi Shimbo; Paul Muntner
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

3.  Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.

Authors:  Lisandro D Colantonio; Keri L Monda; Robert S Rosenson; Todd M Brown; Katherine E Mues; George Howard; Monika M Safford; Larisa Yedigarova; Michael E Farkouh; Paul Muntner
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727

4.  Racial differences in statin adherence following hospital discharge for ischemic stroke.

Authors:  Karen C Albright; Hong Zhao; Justin Blackburn; Nita A Limdi; T Mark Beasley; George Howard; Vera Bittner; Virginia J Howard; Paul Muntner
Journal:  Neurology       Date:  2017-04-12       Impact factor: 9.910

5.  One-year statin persistence and adherence in adults with HIV in the United States.

Authors:  Kaylee B Crockett; Ying Wen; Edgar T Overton; Elizabeth A Jackson; Robert S Rosenson; Paul Muntner; Lisandro D Colantonio
Journal:  J Clin Lipidol       Date:  2020-11-11       Impact factor: 4.766

6.  Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States.

Authors:  Dylan L Steen; Irfan Khan; Katherine Andrade; Alexandra Koumas; Robert P Giugliano
Journal:  J Am Heart Assoc       Date:  2022-04-27       Impact factor: 6.106

7.  Validation of self-reported medication use for hypertension, diabetes, and dyslipidemia among employees of large-sized companies in Japan.

Authors:  Kota Fukai; Tomohisa Nagata; Koji Mori; Makoto Ohtani; Kenji Fujimoto; Masako Nagata; Yoshihisa Fujino
Journal:  J Occup Health       Date:  2020-01       Impact factor: 2.708

8.  Adherence to Statin Therapy Among US Adults Between 2007 and 2014.

Authors:  Lisandro D Colantonio; Robert S Rosenson; Luqin Deng; Keri L Monda; Yuling Dai; Michael E Farkouh; Monika M Safford; Kiran Philip; Katherine E Mues; Paul Muntner
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

9.  Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries.

Authors:  Vera Bittner; Lisandro D Colantonio; Yuling Dai; Mark Woodward; Matthew T Mefford; Robert S Rosenson; Paul Muntner; Keri L Monda; Meredith L Kilgore; Byron C Jaeger; Emily B Levitan
Journal:  JAMA Cardiol       Date:  2019-09-01       Impact factor: 14.676

10.  Tongue Image Database Construction Based on the Expert Opinions: Assessment for Individual Agreement and Methods for Expert Selection.

Authors:  Zhen Qi; Li-Ping Tu; Zhi-Yu Luo; Xiao-Juan Hu; Ling-Zhi Zeng; Wen Jiao; Xu-Xiang Ma; Cong-Cong Jing; Wei-Jian Wang; Zhi-Feng Zhang; Jia-Tuo Xu
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-02       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.